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Abstract
Due to growing throughput and shrinking cost, massively parallel sequencing is rapidly becoming an attractive alternative
to microarrays for the genome-wide study of gene expression and copy number alterations in primary tumors. The
sequencing of transcripts (RNA-Seq) should offer several advantages over microarray-based methods, including the ability
to detect somatic mutations and accurately measure allele-specific expression. To investigate these advantages we have
applied a novel, strand-specific RNA-Seq method to tumors and matched normal tissue from three patients with oral
squamous cell carcinomas. Additionally, to better understand the genomic determinants of the gene expression changes
observed, we have sequenced the tumor and normal genomes of one of these patients. We demonstrate here that our RNA-
Seq method accurately measures allelic imbalance and that measurement on the genome-wide scale yields novel insights
into cancer etiology. As expected, the set of genes differentially expressed in the tumors is enriched for cell adhesion and
differentiation functions, but, unexpectedly, the set of allelically imbalanced genes is also enriched for these same cancer-
related functions. By comparing the transcriptomic perturbations observed in one patient to his underlying normal and
tumor genomes, we find that allelic imbalance in the tumor is associated with copy number mutations and that copy
number mutations are, in turn, strongly associated with changes in transcript abundance. These results support a model in
which allele-specific deletions and duplications drive allele-specific changes in gene expression in the developing tumor.
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Introduction
The development of tools for measuring gene expression and
structural variation across the entire genome has revolutionized
our ability to characterize cancers at the molecular level. However,
such tools have typically relied on microarray hybridization, which
has limited sensitivity and is susceptible to the effects of cross-
hybridization between homologous DNA fragments. The recent
advent of massively parallel sequencing has provided a more
powerful tool to study changes in transcriptomes and genomes,
through what is termed RNA sequencing (RNA-Seq) [1] and
genome re-sequencing [2], respectively. By sequencing the whole
transcriptomes of a tumor and matched normal tissue, we can
compare not only the relative abundance of annotated transcripts,
but also that of non-annotated transcripts, transcript isoforms and
different alleles [3,4,5]. With sufficient sequencing depth, tumor-
specific mutations, which may contribute to pathogenesis, can be
detected. Similarly, by sequencing the genomes of a tumor and
matched normal tissue, structural and point mutations associated
with tumor development can be discovered [6,7,8,9].
Cancers of the head and neck are the sixth most commonly
observed cancers worldwide [10]. Most are squamous cell
carcinomas that commonly occur in the oropharynx and oral
cavity. At the advanced stage, these cancers are highly invasive
and metastatic, with an associated five year survival in the United
States of only 50% [11]. Microarray studies of oral cavity tumors
have revealed genes that are consistently mis-expressed
[12,13,14,15,16], but have not yet led to a panel of genes that
can be used effectively to make informed clinical decisions.
Here we have paired a new strand-specific whole transcriptome
library preparation method with massively parallel ligation
sequencing to study the transcriptomes of three oral squamous
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With the resulting 60 Gb of sequence we performed two types of
analyses. First, we examined differential expression of genes
between tumor and normal tissue across the three patients and
compared these results to those produced by microarray and RT-
qPCR. The comparison reveals strong concordance between the
methods, with RNA-Seq outperforming microarrays at measure-
ment of the low abundance transcripts. Second, we investigated
the extent and types of allelic imbalance (AI) observed between the
tumor and normal tissues of the three patients. Here we focus on
relative AI, which compares the ratio of the expression of two
alleles in one sample (e.g., tumor tissue) to that in another sample
(e.g., matched normal tissue). AI represents a convolution of
genotype and expression level that can arise due to a number of
different processes. Our analysis demonstrates the ability of RNA-
Seq to accurately measure AI and the utility of AI for
understanding cancer development. Unlike other methods, our
RNA-Seq approach surveys strand-specific expression across the
entire length of transcripts, allowing us to observe bidirectional
promoter usage and improving our chances of covering the rare
heterozygous SNPs needed for AI analysis.
We have also sequenced the tumor and normal genomes of one
of the three patients and determined copy number changes present
in the tumor genome. By comparing genomic and transcriptomic
data from this patient, we observe that changes in gene dosage are
strongly associated with changes in gene expression and allelic
imbalance in this tumor. These data are consistent with a model in
which allele-specific duplication and deletion drive allele-specific
changes in gene expression [17,18,19].
Results
Measurement of Gene Expression in OSCC and Normal
Tissue by RNA-Seq
We sequenced rRNA-depleted total RNA extracted from tumor
and matched normal tissue from three patients with oral squamous
cell carcinoma (OSCC) (Methods and Figure S1), yielding 129–
256 million 50 bp long sequence reads per sample. Reads were
aligned first to a filter database (containing, e.g., rDNA sequences)
and then to the human genome (Methods and Figure S2) and an
overview of the results is displayed in Figure 1. The majority of
reads from each sample (57–79%) were successfully aligned; those
that did not align are likely to be polyclonal, low quality or have
origins outside the reference human genome. A large fraction of
the reads from each sample (21–48%) aligned to rDNA, suggesting
that our rRNA depletion efficiency was low, which is most likely
because the RNA isolated from these tumors was partially
degraded (Figure S3). Nevertheless, between 21 and 56 million
reads per sample were uniquely aligned to the human genome
outside of rDNA and over 100,000 of the 195,148 RefSeq-
annotated exons were detected in each sample (Figure 1 and Text
S1). On the whole, we have an unprecedented depth of uniquely
aligned sequence from these tumor and matched-normal RNA
samples.
Given that RNA-Seq is still an emerging methodology, we
wanted to ensure that our method provides gene expression
measurements that are consistent with orthogonal technologies
(e.g., RT-qPCR and microarray). We assessed concordance with
these other methods at the level of differential gene expression
between tumor and normal tissue samples (Methods). The same
six RNA samples used for RNA-Seq were prepared and
hybridized to microarrays that have one probe designed to target
each of the RefSeq transcripts (Methods). The two gene expression
platforms are strongly concordant in the measurement of
differential gene expression between tumor and normal tissue
(r=0.73-0.81; Figure S4 and Tables S1 and S2). However, it is
apparent that the two platforms diverge at low expression levels,
where RNA-Seq often indicates differential expression and the
microarray does not. We randomly selected sixteen of these
divergent genes for validation by RT-qPCR, eight that were up-
regulated and eight that were down-regulated in the tumor relative
to normal tissue, and found that the measurements provided by
RT-qPCR are more highly correlated to those provided by RNA-
Seq (r=0.84), than to those provided by microarray (r=0.71)
Figure 1. Alignment statistics for transcriptome reads from the six clinical samples. Read counts listed in the middle section are expressed
in millions (left column) or as a percentage of the total reads processed (right column) for each sample.
doi:10.1371/journal.pone.0009317.g001
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regression line for the RNA-Seq comparison is 1.0, while that for
the microarray comparison is 0.15, suggesting that the fold-
changes measured by microarray for these genes are strongly
compressed relative to the true fold-changes and helping to explain
the observed discrepancies between the RNA-Seq and microarray
data. These results demonstrate that our RNA-Seq method can
reliably measure gene expression differences in human tissue and
further suggest that RNA-Seq is better at making such measure-
ments when expression levels are low.
A Common Set of Genes Is Differentially Expressed in
OSCC
We next investigated the biological significance of the tumor
versus normal (TvN) expression profiles. First, by hierarchically
clustering the log-transformed transcript expression levels in the
six samples, we established that the same types of tissue from
different patients are more similar than different types of tissue
from the same patient (Figure 2a). Furthermore, we observed
strong correlations (r=0.46–0.62) between the log-transformed
TvN expression profiles between patients (Figure 2b), confirming
that there is a common gene expression perturbation associated
with this disease in different individuals. Close examination of the
relationship between the TvN profiles of different patients
(Figure 2c), revealed that the correlation extends across the entire
range of fold-changes (e.g., r=0.36 for genes with | log2 T/N |,
2.0).
To isolate the set of genes commonly mis-regulated in the
development of OSCC, we took a rank-order approach (Methods
and Tables S1 and S3). We note that an approach employing a
likelihood ratio test [20] yielded similar results (Table S1) that do
not alter any of the conclusion made here. A survey of the genes
most strongly differentially expressed across the three patients,
reveals four particularly interesting genes (Figure 3a–d): (1)
MMP1, which encodes a secreted matrix metalloproteinase that
breaks down interstitial collagens, ranks third amongst the set of
up-regulated genes. MMP1 is part of a family of matrix
metalloproteinases with known roles in invasion and metastasis
[21] and several family members are amongst our most up-
regulated genes (MMP3/10/11/12/15). Unlike microarrays,
which typically measure gene expression in only one or a few
regions of a gene specifically targeted by probes, our RNA-Seq
method measures strand-specific expression across the entire gene,
as can clearly be seen for MMP1 (Figure 3a). (2) INHBA, the
fourth most up-regulated gene across the patients, similarly shows
strand-specific expression spanning its locus (Figure 3b). INHBA
encodes the beta A subunit that, together with an alpha subunit
encoded by INHA, forms inhibin. Inhibin is a pituitary FSH
secretion inhibitor that has been shown to regulate gonadal
stromal cell proliferation negatively and to have tumor-suppressor
Figure 2. A common set of genes is differentially expressed in the tumors of three patients with oral carcinoma. (A) Transcript
expression levels in each of the six samples were hierarchically clustered and, as expected, the normal and tumor tissues form tight clusters. Shades of
blue indicate lowered expression, relative to the mean across samples, whereas shades of yellow indicate higher expression relative to the mean. (B)
For each patient, gene expression in the tumor was compared to that in matched normal tissue. Pearson correlations indicate strong and significant
(P,10
216) similarity of differential transcript expression across the three patients. (C) A scatterplot, comparing differential transcript expression
between patients 8 and 33.
doi:10.1371/journal.pone.0009317.g002
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extracellular matrix digestion and muscle contraction. (A–D) Examples of gene expression at four loci. Plotted across each locus is the
normalized sequence coverage on both the plus (colored red) and minus (colored orange) strands, for the tumor and normal tissue of a particular
patient. (A) MMP1 in patient 51; y-axis scale is 10 to 2000. (B) INHBA in patient 8; y-axis scale is 10 to 150. (C) HMGA2 and RPSAS52 in patient 8; y-axis
scale is 10 to 300 for the plus strand and 10 to 100 for the minus strand. (D) CASQ1 in patient 33; y-axis scale is 10 to 100. (E–F) The most up-regulated
(E) and down-regulated (F) genes in the tumors of the three patients were submitted for gene ontology (GO) analysis [29] to identify biological
processes and components that are typically mis-regulated in oral cancer. Redundant GO categories were filtered. ‘‘Count in category’’ indicates the
total number of genes assigned to a given GO category and ‘‘count in overlap’’ indicates the number of up- or down- regulated genes that are also
assigned to the given GO category.
doi:10.1371/journal.pone.0009317.g003
RNA-Seq of Oral Carcinomas
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9317activity [22]. However, INHBA’s increased expression levels in
these patients’ tumors more likely reflect its product’s ability to
homodimerize and form activin A, an FSH secretion activator and
putative oncogene in esophageal carcinoma [23]. This is consistent
with the apparent lack of expression of INHA in the normal and
tumor tissues of all three patients and implicates INHBA as a
potential oncogene in OSCC. (3) HMGA2 is the eleventh most
up-regulated gene across the patients and is of considerable
interest as a known oncogene [24,25,26], containing an HMG
DNA-binding domain. HMGA2 was not frequently featured in
previous microarray studies of OSCC, possibly due to the low
overall expression of its exons (HMGA2’s expression, as judged by
transcript length-normalized read counts, ranks in the bottom 2%
of all transcripts). In our microarray experiments, we find only
very modest TvN changes in HMGA2’s expression (0.9-, 1.1- and
1.5-fold), compared to those changes measured by RNA-Seq (2.0-,
15.2- and 206-fold). However, as Figure 3c clearly illustrates,
HMGA2’s exonic and intronic regions are strongly up-regulated in
the tumor. Furthermore, we validated HMGA2’s differential
expression by RT-qPCR (Figure S4e, discussed in the previous
section). Interestingly, the up-regulation of HMGA2 coincides
with the up-regulation of a pseudogene for ribosomal protein SA
(RPSAP52), whose expression runs in the opposite direction and
overlaps HMGA2 by roughly 2 kb in patient 8, suggesting that
these two genes share a bi-directional promoter [27,28]. (4)
CASQ1, the sixth most down-regulated gene across the patients
(Figure 3d), encodes calsequestrin, a calcium binding glycoprotein
that localizes to the sarcoplasmic reticulum and may act to store
calcium. The functions of CASQ1 and the three other genes are
emblematic of the functions encoded by the entire set of
differentially expressed genes.
To more systematically assess the biological functions of
commonly mis-regulated genes, we performed gene ontology
(GO) analysis [29]. A selection of the results is displayed in
Figure 3e,f. The process of cell adhesion and components of the
extra-cellular matrix (ECM) feature prominently amongst both the
up- and down-regulated gene sets (shaded blue in Figure 3e,f), of
which MMP1 is a prime example (Figure 3a). The altered
regulation of these genes is consistent with the model that cancer
development involves restructuring of the external environment,
including breakdown of the ECM [30,31], and is also consistent
with previous microarray studies of oral cancer (e.g., [32]). Also
featured in both gene sets are functions related to development
and differentiation (shaded green in Figure 3e,f). Whereas the
down-regulated genes tend to function in epidermal development,
the up-regulated genes more often function in cell motility and
nervous system development, as might be expected for OSCC
[33,34]. Perhaps the strongest trend though, is the massive over-
representation of muscle contraction functions amongst the down-
regulated genes (shaded gray in Figure 3f). Several actins, myosins
and related components of the cytoskeleton are strongly down-
regulated, possibly reflecting a de-differentiation of the muscle
phenotype during oral cancer development. Alternatively, this
may simply reflect the choice of normal tongue tissue as our
control. Alterations to cell adhesion, development, differentiation,
and the ECM are consistent with what is known about this disease.
The results presented here are also consistent with existing
knowledge of gene expression changes in OSCC development. For
example, a meta-analysis of 41 head and neck squamous cell
carcinoma (HNSCC; OSCC is one type of HNSCC) expression
profiling studies identified 25 genes that were differentially
expressed between tumor and normal tissue in nine or more of
these studies [16]. Of these 25 genes, 15 are also in our set of 600
mis-regulated genes, which is much greater than the roughly 1.4
genes expected by chance (hypergeometric P-value,10
212;1 5o f
25, from 10,542 total genes detected) and also much greater than
the mean of 6.8 genes for any given study in the meta-analysis.
Thus, it is evident that the examination of a relatively small
number of OSCC cases by RNA-Seq recapitulates much of the
accumulated knowledge of gene expression alterations in the
development of this cancer, including the mis-regulation of genes
functioning in cell adhesion, development, differentiation, muscle
contraction and the ECM.
There Is Widespread Allelic Imbalance between Tumor
and Normal Tissues
One advantage of our RNA-Seq method is that it allows us to
address questions that were previously inaccessible on the genome-
wide scale. An example is allelic imbalance (AI), which we define
here as a difference in the nucleotide frequencies at a given
transcriptome position between two tissues/conditions (Figure 4a).
AI can arise through one, or a combination of, several processes
acting in one tissue relative to the other: (1) cis mutations that
impact the underlying genomic position directly in one of the two
haplotypes (e.g., a point mutation or a deletion/duplication that
changes the copy number of one allele relative to the other), (2)
indirect cis mutations (e.g., a point mutation in an upstream cis-
regulatory element affecting expression of only that allele), (3)
differences in trans (e.g., mutations to other components of the
transcriptional network that differently affect expression of the
alleles), (4) differences in RNA editing. More simply, AI represents
a convolution of genotype and expression level. Here we
demonstrate that RNA-Seq can be employed to successfully
interrogate AI in tumors, relative to matched normal tissue, across
the whole transcriptome. Although, in general, we will not be able
to differentiate between the four possible underlying causes from
RNA-Seq data alone, we show here that the presence of AI itself is
informative and that straightforward follow-up experiments can be
utilized to identify the root cause.
In principle, our depth of sequencing is sufficient to detect AI in
a large number of exons (Figure 4b); the average per base exon
coverage varies between 5x and 16x, depending on the sample
(Figure 1). However, it is unknown whether the nucleotide counts
accurately reflect the underlying expression of each allele. To
ensure this is the case, we examined the distribution of allelic
ratios. For a given genomic coordinate, the ‘‘allelic ratio’’ is the
number of reads aligned across that position that indicate the
reference nucleotide divided by the number of reads that indicate
the first non-reference nucleotide in dbSNP [35]. Thus we only
concern ourselves here with the subset of genomic positions for
which an allele is listed in dbSNP and to which at least 15 reads
are aligned. If alleles tend to be expressed at equal levels, then we
expect to see a trimodal distribution of allelic ratios, representing
the three possible genotypes: homozygous reference, heterozygous
and homozygous non-reference. However, if our technology does
not accurately quantify the two alleles or if alleles tend to vary
greatly in their expression, then we would expect to see a more
uniform distribution. In fact, clear trimodal distributions are
observed in all six samples (Figure S5) with peaks likely
representing the three genotypes. Thus we are confident that the
nucleotide counts accurately portray the expression levels of the
different alleles.
We next developed a method to detect relative AI between
samples (Methods) and applied it to the three paired samples. Here
we analyze further only those genomic positions having, (1) at least
15x coverage in the tumor and normal samples, (2) significant AI
with x
2 P-value less than 10
23 (Figure S5), and (3) not more than
90% of covering reads supporting each nucleotide aligned to
RNA-Seq of Oral Carcinomas
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9317Figure 4. A common set of genes, functioning in cell adhesion and development, exhibits allelic imbalance in the tumor
transcriptomes of three patients with oral carcinoma. Allelic imbalance (AI) at the RNA level can arise in a number of ways, including through
point mutation and changes in the relative expression of alleles (aka, allele-specific expression). (A) Illustrated is an example of two pre-existing alleles
(G and T), one of which undergoes a linked promoter mutation (red asterisk) in the tumor, relative to the normal tissue. If, for example, the mutation
alters a cis-regulatory element, then the balance of the two alelles (G and T) may change. (B) In principle, there is enough sequence coverage to
discover AI for a large number of exons. For example, more than 25,000 exons have at least 10x coverage (averaged across all sites in the exon). (C)
Genes with one or more instances of allelic imbalance in the tumors of two or more patients were submitted for GO analysis [29] to identify biological
processes and components that are typically allelically imbalanced in oral cancer. Redundant GO categories were filtered. (D) A selection of genes
with allelic imbalance in two or more patients is listed, along with the log2 differential expression of each gene and regions of gene structure
impacted. Also noted is whether or not the gene is involved in cell adhesion or is a component of the ECM. Key: 3=39 UTR, I=Intronic, NSS=Near
Splice Site, Syn=Synonymous, R=Non-Synonymous.
doi:10.1371/journal.pone.0009317.g004
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tion). Presence in dbSNP is not a requirement, thus in theory we
can detect imbalances due to either de novo point mutation or
altered expression of preexisting variants. 1316, 991, and 3221
genomic positions meet these criteria in patients 8, 33, and 51,
respectively, demonstrating that widespread allelic imbalance is
associated with the development of these tumors. In what follows,
we further narrowed our focus to those positions with a greater
than 10% change in the absolute frequency of at least one
nucleotide between the two samples, surmising that these positions
would be of greatest biological interest. After applying this filter,
we are left with 229, 185, and 345 genomic positions from 121,
134, and 209 unique genes in patients 8, 33, and 51, respectively
(Table S4). The sets of genes allelically imbalanced in the three
patients overlap significantly; 20 to 26 genes overlap by pair-wise
comparison (hypergeometric P-values ranging from 10
27 to 10
211)
and seven genes are common to all three patients.
To assess whether or not the allelically imbalanced genes are
biologically meaningful and related to the development of this
cancer, we performed GO analysis[29]. Interestingly, the functions
enriched in the set of 52 genes allelically imbalanced in more than
one patient (Table S5) are largely the same as those enriched in the
set of differentially expressed genes (Figure 4c; compare to
Figure 3e,f). Despite this functional overlap, the actual genes in
these two sets overlap very little (only 4 of these 52 genes are also
in the list of commonly mis-regulated genes from the previous
section; 8% observed versus 12% expected, P-value=0.88),
indicating that allelic imbalance may offer a new avenue for
discovering genes involved in cancer development. This lack of
significant overlap between AI genes and differentially expressed
genes holds true even when the cutoffs used to define the set of
differentially expressed genes are varied substantially (not shown),
which indicates that it would not be possible to detect the AI genes
from differential gene expression data alone. Nevertheless the
functions of these genes indicate they are probably of relevance to
tumorigenesis. To test this further we employed the NextBio
Professional system [36] to search for studies and diseases in which
the set of AI genes were differentially expressed. We found that
most of the top hits were from cancer-related studies and diseases,
such as melanoma [37], follicular lymphoma [38], and squamous
cell lung cancer [39], further demonstrating the relevance of AI to
studies of cancer development.
Of these 52 genes with AI in two or more patients, 23 appeared
particularly interesting and are highlighted in Figure 4d. Among
these 23 we detect two cases of apparent non-synonymous point
mutations (within DST and GJB2), where only one nucleotide was
sequenced in the normal tissue and two were sequenced in the
tumor (and the second is not present in dbSNP). Similarly, we
observe one case of point mutation in the 39 UTR of a gene (for
KRT1) and a couple cases of apparent point mutations within 10
bp of a splice site (for DST and S100A2). Changes that apparently
reflect a loss of heterozygosity or complete silencing of one allele in
the tumor are even more frequent. In several cases, these result in
higher expression of an allele that has a non-synonymous or 39
UTR mutation relative to the other allele (e.g., DST, CCND1,
DSP, PKP1, KRT6A, ALDH3A1, DSC3, FAT2 and GJB2). We
have performed extensive validation of our AI results as described
in the Methods section and depicted in Figure S6. Among those
genes with validated AI is DST, a member of the plakin protein
family of adhesion junction plaque proteins. While the expression
of DST in tumor versus normal changes only very modestly across
patients (less than 2-fold), DST is among the small set of genes that
are allelically imbalanced in all three patients. Furthermore, DST
has been shown to be perturbed in studies of other cancers, such as
squamous cell carcinoma of the lung [40], making it an interesting
target of further study.
One particularly convincing example of AI is observed for
transcripts of the adjacent IGF2 and H19 genes (Figure 5), which
are implicated in carcinogenesis and encode an insulin-like growth
factor and a non-coding RNA, respectively [41,42,43,44]. There
are seven genomic positions in these two genes that are allelically
imbalanced in patient 8. The seven positions are located within a
135 kb window on chromosome 11 and all are polymorphic in the
human population, increasing the likelihood that patient 8 may be
heterozygous at these sites. All seven sites show a striking pattern:
while one nucleotide is sequenced in the normal tissue, it is
primarily another nucleotide that is sequenced in the tumor tissue.
We tested and verified that patient 8 is indeed heterozygous at five
of these seven sites by allele-specific qPCR (as-qPCR) of normal
and tumor genomic DNA (the other two sites were not tested;
Methods and Figure S6a). We also validated the observed changes
in allele-specific expression by allele-specific reverse transcription
qPCR (as-RT-qPCR) of normal and tumor cDNA (Figure S6a).
Interestingly, H19 and IGF2 are imprinted in the germline by
methylation and are normally only expressed in somatic tissues
from the maternal and paternal alleles, respectively [43,45]. Thus,
the simplest explanation for these observations is that there was
mono-allelic expression of H19/IGF2 in the normal tissue, which
was subsequently lost or allelically switched during tumor
development. Loss of imprinting is frequently observed in the
Figure 5. A switch in the genomic imprinting of H19 and IGF2. There are six sites in H19 (shaded orange) and one in IGF2 (shaded blue) on
chromosome 11 that are apparently heterozygous in patient 8 (five were validated by as-qPCR). In normal tissue, most detectable expression of H19 is
from one allele, as expected for this imprinted, maternally expressed gene. Unexpectedly, in the tumor, nearly all detected expression is from the
other, presumably paternal, allele. Observed nucleotides are from dbSNP[35].
doi:10.1371/journal.pone.0009317.g005
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tumorigenesis [49]. However, this is the first time, to our
knowledge, that expression has been observed to flip from one
allele to the other.
In summary, our whole transcriptome sequencing approach
allows detection of AI across a large number of genes. AI is a
widespread phenomenon in oral cancer development, impacting
genes known or likely to be involved in cancer etiology. AI’s
presence can be used effectively to identify key cancer develop-
ment events, such as non-synonymous point mutations, loss of
imprinting, loss of heterozygosity, and copy number changes
resulting in up-regulation of one allele relative to the other.
However, resolving ambiguity between these possible underlying
causes currently requires follow-up experiments.
Structural Variation Underlies the Gene Expression
Changes Observed in One Patient
There is abundant copy number variation (CNV) in mamma-
lian populations [50,51], which can sometimes be associated with
changes in the expression of overlapping and nearby genes [52,53]
and also with human traits and diseases [54,55]. We sought to
understand whether copy number (CN) mutations in OSCC
development were driving the changes in gene expression we
observed. We therefore sequenced the tumor and normal genomes
of patient 8, to obtain sequence coverage of ,0.8x (Methods). We
applied a recently developed CNV segmentation algorithm [56],
designed for paired-sample next-generation sequence data, to the
resulting read sequence alignments (Methods). This produced 328
genomic segments, with TvN copy number changes (CNCs)
ranging from 0.4 to 8.8 (Table S6). An array comparative genomic
hybridization (aCGH) experiment was performed on the same
tumor sample, resulting in highly concordant CN segments
(Methods and Figure S7b). CNCs were also validated at 23
particularly interesting genes by qPCR on the samples of patient 8
and across a panel of OSCC tumors obtained from 13 additional
patients. For patient 8, 22 of 23 CNCs were successfully validated
(Figure S7a). Across the panel of other patients, CNCs at these 23
genes ranged in prevalence from 7% to 43%, with a mean of 24%
(Figure S7c).
To compare the CNCs observed between normal and tumor
tissue to changes in gene expression, we calculated the differential
expression of each genomic segment (Methods). The log2-
transformed CNC and log2-transformed normalized gene expres-
sion ratio for each CN segment were then plotted (Figure 6a),
revealing a strong relationship between CNCs and changes in gene
expression (r=0.73).
One particularly remarkable example of concordant change in
CN and gene expression involves the 9x amplification of a 1.5 Mb
segment of chromosome 11 (Figure 6b). Two immediately
adjacent segments, roughly 0.3 Mb and 1.0 Mb in length, are
also amplified (4x and 3x, respectively), suggesting that multiple,
nested duplications gave rise to the amplified state observed in the
tumor. Contained within the three amplified regions are ,20
genes, several of which have been highlighted for their functional
relevance and frequent amplification in OSCCs [57]: Cyclin D1
(CCND1) is an oncogene previously implicated in several cancers
[58] and is 13-fold up-regulated in the tumor. Cortactin (CTTN),
which is often over-expressed in HNSCCs [59] and helps organize
the cytoskeleton and cell adhesion structures of epithelia and
carcinoma cells, is 14-fold up-regulated. Finally, SH3 and multiple
ankyrin repeat domains 2 (SHANK2), which binds the SH3
domain of cortactin and is thereby thought to promote cell motility
at growth cones of neurons [60], is 51-fold up-regulated in the
tumor. Copy number changes in CTTN and SHANK2 were
strongly and equally prevalent across our panel of 14 patients
assayed by qPCR (43%; Figure S7c).
Another striking example of concordant copy number and gene
expression change occurs on chromosome 9, where a 90 kb
genomic segment, containing two genes, has apparently been
deleted in the tumor (Figure 6c). One gene, cyclin-dependent
kinase inhibitor 2B (CDKN2B), falls completely within the deleted
region. CDKN2B controls G1 cell cycle progression by inhibiting
Cdk4 or Cdk6 [61]. Its cell growth regulation function and 120-
fold down-regulation in the tumor make it a strong candidate for a
tumor suppressor [62]. Copy number changes at CDKNB were
prevalent across our panel of 14 patients (29%; Figure S7c).
CDKN2B’s neighbor, cyclin-dependent kinase inhibitor 2A
(CDKN2A), functions similarly to inhibit Cdk4 and is a known
tumor suppressor [63], but is not detectably expressed in either
normal or tumor tissue.
It is also worth noting the amplification of Wnt inhibitory factor
1 (WIF1), which encodes an extracellular component of the Wnt
pathway that plays a critical role in regulating cell adhesion,
proliferation and differentiation [64,65]. Despite its amplification,
WIF1’s expression is strongly down-regulated across the three
tumors for which RNA was sequenced, demonstrating that
amplification does not always imply increased expression. Down-
regulation of WIF1 has been reported in prostate, breast, lung,
bladder, salivary gland and esophageal cancers [66,67] and
evidence of promoter hypermethylation in Barrett’s esophagus
cases that progress to esophageal adenocarcinoma suggests that
loss of expression likely represents an early event in carcinogenesis
[66]. Copy number change at WIF1 was 36% prevalent across the
14 tumors for which we measured CNC, but interestingly the
direction of change was not consistent: two of the tumors had
WIF1 amplifications and three others had deletions. This suggests
that the down regulation of WIF1 can arise not only from
epigenetic alterations, but also from deletion and rearrangement
events and that loss of WIF1 expression may be involved with
carcinogenesis of OSCC.
Finally, we examined the relationship between allelic imbalance
and copy number change. Given that gene dosage changes are
strongly associated with gene expression changes, it is expected
that heterozygous amplifications and deletions will be associated
with the allelic imbalance of transcripts. For example, if one allele
of a genomic region is amplified 10-fold relative to the other allele,
then we might expect to see a 10-fold imbalance of heterozygous
SNPs that fall within the region (depending on the exact
mechanism of amplification). We grouped each copy number
segment into one of three log2-transformed CNC categories,
disregarding the direction of change: low or no CNC
(|CNC|,1.2), moderate CNC (1.2,|CNC|,1.8), and large
CNC (|CNC|.1.8). We then considered the distributions of AI
for genomic regions in each of those CNC categories (Figure 6d).
Here we consider only genomic positions, (1) with at least one
allele in dbSNP, and (2) at which the two nucleotides (reference
and first dbSBP allele) are present in at least four reads in the
normal tissue sample. These two criteria ensure that the patient is
very likely to be heterozygous at such positions in his normal
tissue. Because we do not know a priori which allele has changed in
copy number, we consider only the absolute value of AI. As
depicted in Figure 6d, the moderate and large CNC categories are
significantly shifted to higher levels of AI, relative to the low/no
CNC category (Mann-Whitney P-values 10
210 and 10
23,
respectively). Thus, CNC is associated with increased AI in this
patient’s tumor. For example, the region of chromosome 11
mentioned above for its 9-fold amplification in the tumor, harbors
two expressed heterozygous SNPs within one gene, CCND1. As
RNA-Seq of Oral Carcinomas
PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9317Figure 6. Large structural mutations are strongly correlated with the changes in gene expression observed in one patient’s tumor.
(A) A strong correlation (r=0.73) is observed between changes in copy number and changes in gene expression for patient 8. The correlation is
stronger (r=0.84) if only copy number changes greater than 1.4-fold are considered. (B) The most strongly amplified region (9-fold more copies in
the tumor than normal; chr11:68,503,204-69,987,273) contains several differentially expressed (red and orange tracks) genes, highlighted in the text.
(C) One region (chr9:21,973,361-22,061,522) that is likely to have been deleted in the tumor contains two genes of interest: cyclin-dependent kinase
inhibitor 2B (CDKN2B) and cyclin-dependent kinase inhibitor 2A (CDKN2A). (D) Given that gene dosage changes are strongly associated with gene
expression changes, it is expected that heterozygous amplifications and deletions will be associated with the allelic imbalance of transcripts. Shown
are the distributions of allelic imbalance for genomic regions that fall into one of three categories of log-transformed copy number change (CNC): low
or no CNC (blue; |CNC|,1.2), moderate CNC (red; 1.2,|CNC|,1.8), and large CNC (yellow; |CNC|.1.8). The moderate and large CNC distributions are
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chromosomes and not the other, the sites are more than 16-fold
imbalanced in the tumor compared to the normal tissue, a result
which we validated by as-qPCR of genomic DNA and cDNA
(Figure S6).
Taken together, these results show a strong relationship between
structural mutations and changes in gene expression in this
patient’s tumor. Increased gene dosage is associated with increased
gene expression and decreased gene dosage is typically associated
with decreased gene expression. Furthermore, gene dosage
changes are linked with changes in the relative expression of
alleles. The simplest interpretation is that the allele-specific
structural mutations in this patient’s tumor have driven the
observed changes in gene expression.
Discussion
By sequencing the tumor and normal transcriptomes of three
individuals with OSCC, we have characterized, in depth, the
changes in gene expression associated with development of this
cancer. We have demonstrated that our RNA-Seq method can be
successfully applied to profile gene expression in tumor and
matched normal tissues, in much the same way that microarrays
have been applied to this task in the past. The gene expression
profiling results we produced by sequencing are largely concordant
with those we produced from hybridizing the same samples to
microarrays (Figure S4). However, as we have shown here by RT-
qPCR, sequencing is a superior approach for measuring
differential expression of genes expressed at low levels, at least
for samples of imperfect quality, such as the clinical tissue samples
studied here. For example, the 206-fold up-regulation of the
transcriptional regulator and oncogene HMGA2 in one tumor
would have been missed if only assayed by microarray (Figure 3c
and Figure S4e). In general, we expect that deep sequencing
methods will better detect perturbations in the expression of genes
encoding transcription factors and signaling proteins, which tend
to be expressed at lower levels than other genes in the cell [68].
HMGA2 also has a transcriptional coverage profile that indicates
it shares a bi-directional promoter with RPSAP52 (Figure 3c),
neatly demonstrating the added insights possible with a strand-
specific, whole transcriptome approach to RNA-Seq.
Not only have we demonstrated the overall similarity of results
obtained by deep sequencing and microarray hybridization of the
same samples, but we have also shown that both sets of results are
in strong agreement with existing knowledge of this cancer.
Development of OSCC involves perturbed regulation of genes
functioning in interaction with the external environment, such as
those functioning in cell adhesion and encoding components of the
extra-cellular matrix (Figure 3a,e,f). Our functional analysis also
indicates extensive down-regulation, in the tumors, of genes
functioning in epidermal development and up-regulation of genes
functioning in cell motility. The strongest gene expression
signature observed is the down-regulation in tumors of many
genes with muscle contraction functions (Figure 3e,f), indicating
that the development of this cancer may involve the reversal of
muscle cell differentiation found in the oral tongue. In addition, we
have now identified specific genes (e.g, INHBA and WIF1), which
while previously implicated in other cancer types, to our
knowledge have not previously been implicated in carcinogenesis
of OSCC.
Although deep sequencing, like microarray hybridization, is well
suited to the task of profiling gene expression across tissues and
individuals, it is also capable of interrogating aspects of gene
expression that have typically eluded microarrays (e.g., detecting
the presence of novel, alternative splice forms [4]). Here we have
studied allelic imbalance, another aspect of gene expression that is
difficult to study by microarray. The detection of imbalanced
expression of alleles in cancer samples is a new and potentially
powerful way to gain insights into cancer biology. Deletions,
amplifications, point mutations and changes in the cis regulation of
genes should all be reflected in the relative expression of alleles.
We have scanned each normal and tumor transcriptome and
assessed at each position the relative frequencies of the nucleotides
sequenced. We conclude there is widespread allelic imbalance
between normal and tumor samples: 185 to 345 sites from 121 to
209 unique genes passed our very conservative criteria. Interest-
ingly, the three patients studied share many more allelically
imbalanced genes than expected by chance, but the specific sites at
which AI was detected typically differ between patients. It is
remarkable that the set of genes allelically imbalanced in more
than one patient is enriched for the same cancer-related functions
as the set of differentially expressed genes (compare Figure 4c to
Figure 3e,f), despite the fact that most of the AI genes are not
themselves differentially expressed (Figure 4d). This latter
observation may indicate that perturbation of the most differen-
tially expressed genes tends to occur through trans regulatory
mechanisms affecting both alleles. It also suggests that among the
vast number of genes with changed expression in a tumor, some of
the most causally relevant are those that change very little. For
example, it is easy to imagine how a small perturbation to a central
signaling protein may have large downstream effects. The
observation that these genes are frequently perturbed in other
cancers further argues for the relevancy of the AI genes. Overall,
these results suggest that allelic imbalance may play a broad role in
cancer biology and that its detection may provide a fruitful and
novel avenue towards the discovery of new cancer genes. The
development of more sophisticated algorithms for detecting and
classifying AI along with the integration of complementary
genotypic data, should allow greater insights into the mechanisms
underlying AI and thus the genetic and epigenetic bases for
development of various cancers. However, even with our
rudimentary approach we have already observed changes that
deserve further study, such as the allelic imbalance of DST and the
possible imprinting switch at the IGF2/H19 locus (Figure 5). The
possibility that imprinting was not only lost, but actually reset in
development of this cancer, is intriguing and analogous to the
phenomenon of epigenetic reprogramming that occurs during
germ line development [69].
Finally, the combination of transcriptome sequencing and
genome sequencing affords the opportunity to characterize the
genomic mutations underlying alterations in gene expression in a
tumor. We sequenced the tumor and normal genomes of one
patient and used these data to determine copy number changes
(CNCs) between the two samples. Highly concordant results were
obtained by other methodologies (qPCR and aCGH; Figure S2),
thereby validating the use of deep sequencing to measure CNC in
primary tumors. We directly compared the CNCs identified in this
tumor to changes in the tumor’s transcriptome across the same
genomic regions and thereby observed a strong correlation
between changes in copy number and changes in gene expression
(Figure 6a,b,c), an association that has been observed for other
cancers in the past [70,71]. Thus, much of the up- and down-
regulation of genes observed in this tumor is likely to be driven by
direct amplifications and deletions of the genomic regions
containing these mis-regulated genes. Consistent with this model
and the idea that deletions and amplifications in the tumor will
tend to be allele-specific, we observe that the expression of
heterozygous SNPs falling within CNV regions is significantly
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outside of CNV regions (Figure 6d). Although the number of
samples examined here is low and thus the wider biological
conclusions only preliminary, we believe the experimental and
analytical methods developed and combined here offer a first
glimpse at the power of pairing genomic and transcriptomic
sequencing to understand the genetic basis of cancer development.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Mayo Clinic. All patients
provided written informed consent for the collection of samples
and subsequent analysis.
Collection and Processing of Tissues
All tissues used in this study were collected from patients
undergoing treatment at Mayo Clinic, Rochester, MN. Tumor
samples were obtained from patients undergoing surgical treat-
ment for oral squamous cell carcinoma (OSSC). Normal samples
were collected from the negative surgical margins. Following
surgical excision, a portion of the tissue was immediately processed
and snap-frozen in liquid nitrogen for storage and future use. The
remainder was processed for clinical examination and long-term
storage in the tissue archives of Mayo Clinic, Rochester MN,
according to standard clinical protocols. All patients consented to
the use of their tissue for research and this study was approved by
the Mayo Clinic Institutional Review Board. Each collected
sample was frozen sectioned, changing the blade between samples,
and mounted on positively charged glass slides that were stained
with haematoxylin and eosin (H&E) by the Mayo Tissue and Cell
Molecular Analysis Core facility. These slides were then evaluated
by a qualified Mayo Pathologist (J. Lewis) to confirm the presence
or absence of tumor in each sample. Appropriate tumor was
circled and extreme care was taken to obtain only tumor-
containing sections for subsequent isolation of DNA or RNA.
DNA and RNA Extraction
Frozen tissues were compared to corresponding H&E slides
following evaluation by pathology to verify classification of tumor
or normal tissue status. Portions of tissue were removed for nucleic
acid extraction, using disposable scalpels, in quantities ,30mg.
DNA was extracted from frozen tissue using the Invitrogen
PureLink Genomic DNA Mini kit (Carlsbad, CA) according to the
manufacturer’s protocol. Total RNA was extracted from portions
of the frozen tissue samples using the Qiagen RNAeasy Plus Kit
(Valencia, CA) according to the manufacturer’s protocol. Isolated
DNA and RNA were quantified by NanoDrop ND1000 (Thermo-
Fisher Scientific, Waltham, MA). RNA samples were further
assessed for quality using the Agilent 2100 Bioanalyzer (Santa
Clara, CA) prior to library construction.
RNA Library Preparation
To construct libraries suitable for SOLiD
TM System sequenc-
ing, 5 ug of total RNA was depleted of 18S and 28S rRNA using
GLOBINclear
TM (Ambion) buffers and reagents supplemented
with biotinylated capture probes designed against these rRNAs
and following the given protocol. The rRNA depleted samples
(,1 ug) were then fragmented by incubation with 1 unit of RNase
III (Ambion) for 10 minutes in a 10 ul reaction volume containing
1X RNase III buffer supplied with the enzyme. The samples were
then mixed with formamide gel loading dye and denatured for
10 min at 95uC and then separated on a flashPAGE
TM gel
apparatus using a modified procedure. The flashPAGE
TM gel was
first run for 15 minutes as per the given procedure and conditions.
The lower running buffer was then removed and the lower
chamber rinsed with nuclease-free water 2 times. The lower
chamber was then replenished with fresh buffer and the gel was
run for an additional 45 minutes. The lower running buffer was
then removed and the RNA was purified using the flashPAGE
TM
clean up kit, producing RNA fragments ranging from ,50–150 nt
in size. This RNA was then used with the SOLiD Small RNA
Expression Kit (Ambion) as per the given protocol, except the size
range of products purified from the 6% native PAGE step was
,140–200 bp in size. The final purified products were quantitated
using a nanodrop and the size range of the products was confirmed
by bioanalyzer analysis. The samples were then diluted and used
for emulsion PCR.
DNA Library Preparation
10 ug of each DNA sample was used to generate mate-paired
libraries with a 2.5 kb insert size using standard manufacturer
protocols. Briefly, DNA was sheared to a target size of 2.5 kb using
a HydroShearH (Genomic Solutions). The resulting fragments
were end repaired using the End-It
TM (Epicentre) kit, methylated
to protect EcoP151 sites, and ligated to CAP adapters. The DNA
was then size selected by electrophoresis on a 1% agarose gel, and
a band 2 kb to 3 kb was excised from the gel using a scalpel blade.
DNA was recovered from the gel using QIAquick Gel Extraction
Kit (Qiagen). The resulting DNA fragments were circularized by
ligation to an internal adapter, and 25–27 bp ‘mates’ created by
digestion with the type III restriction enzyme EcoP151. Double
stranded P1 and P2 sequencing adapters were then ligated to the
library and nick translated before final amplification using 14–15
cycles of PCR. Libraries were again purified by electrophoresis on
a 3% agarose gel, excising the appropriate library band and
recovering the DNA using the QIAquick Gel Extraction Kit
(Qiagen). The size, quantity and quality of the resulting libraries
were confirmed by analysis on a 2100 Bioanalyzer (Agilent) using a
DNA 1000 chip before the library was diluted and used for
emulsion PCR.
Emulsion PCR
Templated beads were generated for sequencing using standard
manufacturers’ protocols. Briefly, an aqueous phase was prepared
from the SOLiD ePCR kit containing AmpliTaq Gold DNA
Polymerase UP, buffer, MgCl2, dNTP’s, amplification primers and
library template. The aqueous phase was then introduced to a
whirling oil phase in an ULTRA-TURRAXH Turbo Drive (IKA)
to create a water-in-oil emulsion. The emulsion was then
transferred to a 96 well plate and thermocycled using the
recommended PCR conditions. After PCR amplification, emul-
sions were broken using butanol, and the beads were washed,
enriched, and terminal transferased before quantification and
deposition onto a slide for sequencing.
Whole Transcriptome Sequencing
Templated beads were deposited onto one full slide per sample.
Massively parallel ligation sequencing was carried out to 50 bases
using Applied Biosystems SOLiD System (V3 chemistry) and
following the manufacturer’s instructions.
Mate-Pair Genome Sequencing
Templated beads for the normal and tumor samples were
deposited across two sequencing slides, three quadrants per
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libraries were sequenced to 25 bases, using Applied Biosystems
SOLiD System (V3 chemistry) and following the manufacturer’s
instructions.
Alignment of Transcriptome Fragment Reads
Whole transcriptome reads were aligned using AB’s SOLiD
Whole Transcriptome Pipeline [72]. This software is open-source
and freely available (http://solidsoftwaretools.com/gf/project/
transcriptome/). An overview of the alignment strategy is
presented in Figure S2. In all the analyses of gene expression
presented here, only uniquely aligned reads were considered. A
‘‘uniquely aligned’’ read is defined as a read with a max scoring
alignment to the genome scoring (1) at least 24 and (2) at least four
higher than any of the other alignments of that read to the
genome. Exon locations described in the text were taken from the
alignments of RefSeq transcripts to version 18 of the human
genome sequence (hg18), and are available at the UCSC Genome
Browser website (http://genome.ucsc.edu/). All sequence data has
been deposited at the MIAME compliant Gene Expression
Omnibus (GEO) database at National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/geo) and is accessible
through accession number GSE20116.
Alignment of Genomic Mate-Pair Reads
Mapping and pairing were performed with Applied Biosystems’
alignment and pairing package (corona_lite, http://solidsoftwaretools.
com/gf/project/corona/). The AB SOLiD alignment tool, mapreads,
translates the reference sequence to dibase encoding (color space) and
aligns reads in color space. The program guarantees finding all
alignments between a read and the reference sequence with up to M
mismatches (a user specified parameter, which was set to two here).
Mapreads uses multiple spaced seeds (discontinuous word patterns) to
achieve a rapid running time (Zhang et al., in preparation). Reads that
align to the color space reference in only one location with up to two
mismatches are referred to as ‘‘uniquely aligned’’. Mate-pair reads
were aligned individually and subsequently a pairing process was
conducted to pair the individual reads. Pairing rescue was also
performed, which uses one aligned tag as an anchor and searches for
the other tag in a nearby window (of 1.4–3.7 kb, either upstream or
downstream, depending on orientation of the anchored tag) with more
relaxed criteria.
Quantification of RefSeq Transcripts from RNA-Seq Data
For each of the 18,095 RefSeq transcripts, reads uniquely
aligned within its genome-mapped exons were summed. One
pseudo-count was added to this sum and the resulting modified
raw transcript count was divided by the total number of uniquely
aligned reads for the sample, yielding normalized transcript counts
for each RefSeq transcript in each sample. Normalized transcript
counts and TvN fold-changes can be found in Table S1. Because it
is not yet clear whether genes expressed at the very lowest levels in
a tissue are accurately measured by these methods, we applied a
conservative raw count filter throughout our analysis of the RNA-
Seq data, requiring that a transcript have at least fifty uniquely
aligned reads in at least one tissue (tumor or normal) in all three
patients. We did not normalize for transcript length because all
further analyses focused on fold-changes between two conditions.
Defining the Sets of Genes Mis-Regulated Across the
Patients
To isolate the set of genes commonly mis-regulated in the
development of OSCC, we rank ordered the TvN fold-changes for
each patient. We then ranked transcripts by their median TvN
rank across patients, considering further only the three hundred
highest and three hundred lowest ranking genes as the sets of genes
commonly up-regulated and down-regulated in OSCC develop-
ment, respectively. Gene sets can be found in Table S3. The three
hundred most up-regulated and down-regulated genes have
median fold-change cutoffs of at least 3-fold, though typically
the median fold changes are much higher, with a mean of 6-fold
for the up-regulated genes and 33-fold for down-regulated set. A
simulation, in which the pairing of transcripts and expression levels
is randomly shuffled, indicates that less than 10% of our down-
regulated and 20% of our up-regulated genes would have as
extreme a median rank if there was no similarity in TvN
expression profiles between patients (not shown). Thus, we
estimate that these sets contain relatively few false positive genes,
which are not truly differentially expressed across these three
patients.
Although rank ordering was our original approach, we have also
employed a recently proposed likelihood ratio test combined with
a fold-change cutoff to define sets of mis-regulated genes [20]
(Table S1). Using this statistical test (specifically, an FDR cutoff of
10
24 and 4-fold change requirement) results in very similar lists of
up- and down-regulated genes. We performed GO analysis on the
sets of up- and down-regulated genes defined in this manner and
found that the resulting enriched biological functions are also very
similar to before, changing none of our conclusions.
Gene Expression Validation by Microarray
mRNA samples were reverse transcribed by priming off the
polyA tail, producing cDNA pools. Each cDNA pool was
amplified by in vitro transcription, generating biotin-labeled cRNA
that was then hybridized to an Illumina HumanHT-12 v3
BeadChip array. Arrays were subsequently stained with Strepta-
vidin-Cy3 and scanned with a high resolution Illumina scanner to
determine fluorescence intensities. The raw intensity files from the
arrays were pre-processed using Illumina’s BeadStudio software
for background subtraction and quantile normalization, producing
normalized intensity values for each gene. Differential gene
expression values, between the tumor and normal tissues of a
particular patient, were compared with the corresponding values
from RNA-Seq data (Table S2). The differential expression of a
gene was calculated by applying a log2 transform to the ratio of
modified, normalized intensities in the tumor and normal samples
of a patient. The modified, normalized intensity for a gene was
derived from its normalized intensity by subtracting the minimum
normalized signal intensity across all genes in the sample and
adding a value of one (to avoid dividing by zero). All microarray
data is MIAME compliant and the raw data has been deposited at
the MIAME compliant Gene Expression Omnibus (GEO)
database at National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/geo) and are accessible through
accession number GSE19089.
Gene Expression Validation by Reverse Transcription
Quantitative PCR (RT-qPCR)
cDNA was produced using 2 ug of isolated RNA and the High
Capacity cDNA Reverse Transcription Kit with RNase Inhibitor
(P/N 4374966, Applied Biosystems, Foster City, CA). A total of
250 ng of the cDNA product was preamplified using the Applied
Biosystems TaqManH PreAmp Master Mix Kit according to
standard protocol (P/N 4391128). Briefly, 250 ng of cDNA was
amplified for 14 cycles with a pool of 20X TaqMan Gene
Expression Assays specific to the target genes (P/Ns 4331182 and
4351372, Applied Biosystems). Following preamplification, the
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preamplified cDNA was used in individual quantitative PCR
reactions including TaqMan gene expression assays to measure
the expression levels of target genes. To normalize the expression
levels of each target gene, the cycle threshold (CT) of an
abundantly-expressed control gene (GADPH, GUSB, PGK1,
TBP; P/Ns 4333764F, 4333767F, 4333765F and 4333769F) was
subtracted from the CT for each target gene of interest. This value
was then used to calculate log gene expression changes across
samples/conditions (ddCT).
Allelic Imbalance Analysis and Validation
Allelic imbalance (AI) is a difference in the nucleotide
frequencies at a given genomic position between two RNA
samples. To quantify AI at each position in the genome, our
method first tallies di-colors from reads aligned to that position
that represent either a reference nucleotide or a single nucleotide
substitution, filtering from further analysis invalid di-colors, which
likely represent sequencing errors or more complex mutations.
The nucleotide frequencies are then compared between samples
and the significance of the AI is determined by applying a x
2 test of
independence (on a 264 contingency table).
In our first attempt to investigate AI we only required that each
genomic position have: (1) at least 15x coverage in the tumor and
normal samples, (2) significant AI with x
2 P-value less than 10
23,
and (3) more than a 10% change in absolute frequency of at least
one allele. Using these criteria, our first round validation of 27
genomic positions by allele-specific PCR (as-PCR) yielded a 67%
false positive rate (Figure S6), 72% of which could be attributed to
false heterozygous genotypes (i.e., as-PCR of genomic DNA
showed only one allele was present, whereas RNA-Seq found two).
Upon careful examination we realized that two characteristics
were prevalent amongst the false positives and not amongst the
true positives. The first characteristic of false positives is that most
have more than 90% of the reads supporting at least one
nucleotide aligned to identical positions in the genome. In many of
these cases a non-reference nucleotide was observed in only one of
the two samples (normal or tumor) and that nucleotide was not
present in dbSNP. We think these cases are likely attributable to
errors introduced during reverse transcription that are subse-
quently amplified and over-sampled in later steps of the
experimental protocol. Thus, in our second attempt to investigate
allelic imbalance we added another criterion, requiring that at
each genomic position, (4) less than 90% of the reads supporting
each nucleotide can be aligned to identical positions in the
genome. The second characteristic of false positives is that some
tend to occur towards the end of alignments where there is some
uncertainty about the pairing of read and genomic sequence. This
mis-pairing can arise at a splice junction boundary when there is
sequence similarity between the 59 end of the intron and the 59
end of the downstream exon. Thus in our second attempt to
investigate allelic imbalance we conservatively discarded the last
five colors of each read alignment. Employing this added criterion
and filter reduced the false positive rate to 7%, while generating
only one false negative (false negative rate is 4%) on the first round
data. A second round of validation was also undertaken on a new
set of 34 genomic positions, chosen prospectively with these
revised criteria. For this second validation round we saw the false
positive rate drop to 43%, only 27% of which could be attributed
to false heterozygous genotypes from RNA-Seq. Thus these
revised criteria have considerably improved our specificity and
reduced artifacts likely arising from errors in reverse transcription
that are subsequently over-sampled during sequencing.
Allelic Imbalance Validation by Allele-Specific qPCR
(as-qPCR) and Allele-Specific Reverse Transcription qPCR
(as-RT-qPCR)
cDNA was produced by reverse transcription using the High
Capacity Reverse Transcription Kit (P/N 4322171, Applied
Biosystems) and manufacturer’s instructions. as-qPCR and as-
RT-qPCR were performed on an Applied Biosystems 7900HT
Sequence Detection System. The 10 ml PCR mixture contains
diluted RT products (for as-RT-qPCR) or 3 ng genomic DNA (for
as-qPCR), 1x TaqManH Genotyping Master Mixture (P/N
4371357, Applied Biosystems), 0.3 mM allele-specific forward
primer, 0.2 mm TaqManH probe, and 0.9 mm reverse primer.
The reactions were incubated in 384-well plate at 95uC for 10
minutes, followed by 2 cycles of 95uC for 15 seconds and 58uC for
1 minute, and 48 cycles of 95uC for 15 seconds and 60uC for 1
minute. All allele-specific forward primers, TanManH probes and
reverse primers were manufactured at Applied Biosystems. For
each genomic coordinate of interest, each allele was quantified (in
each gDNA and cDNA sample) by obtaining CT values from at
least two (and typically three) replicate reactions. The mean across
reactions was computed and a dCT value calculated by
subtracting the mean CT value for the second allele from the
mean CT value for the first allele. Genomic coordinates with
gDNA assays yielding absolute dCT values greater than 4.0 were
deemed to be homozygous for the allele with lower CT value,
while all others were assigned a heterozygous genotype (Figure
S6a). Allelic imbalance of RNA between tumor and normal
samples was estimated by calculating a ddCT value for each
genomic coordinate assayed, by simply subtracting the dCT value
of the normal cDNA sample from the corresponding dCT of the
tumor cDNA sample. ddCT values were then compared to allelic
imbalance measurements made by RNA-Seq (Figure S6).
Analysis of Copy Number Variation (CNV)
The ratio of the number of uniquely aligned reads in paired
tumor and normal samples for any given genomic sequence
window is an estimate of the copy number change in the window.
We modified Segseq [56], a recently developed CNV calling and
segmentation algorithm that is based on this principle, to handle
SOLiD system sequencing reads. The SegSeq implementation can
not effectively handle the large volumes of data produced here due
to memory limitations, so we divided our original datasets (,50M
reads per sample, ,0.8x sequence coverage) into random subsets
(,12M reads each, ,0.2x sequence coverage). We then applied
the modified algorithm to each subset of the mate-pair reads from
the normal and tumor samples of Patient 8. Reassuringly, the
algorithm produced very similar results on the random subsets of
data (not shown). Default parameters for Segseq were used: the
size of local windows (-W)=400; the size of alignable windows
(-d, -e)=100 kb. The P-value cutoffs, pinit and pmerge, that control
genome wide false positive CNV segments, were set such that we
generated 1 false positive segment from about 20–30 false positive
initial break points (see Chiang et al. [56] for details). Segments are
listed in Table S6.
Calculation of Differential Gene Expression Across Copy-
Number Segments
To compare the CN changes observed between normal and
tumor tissue to changes in gene expression, we calculated the
differential expression of each genomic segment simply by
summing the number of reads uniquely aligned to this region in
the tumor sample and dividing it by the number of uniquely
aligned reads to this region in the normal tissue sample. The
RNA-Seq of Oral Carcinomas
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uniquely aligned for each sample.
Copy Number Validation by qPCR
TaqMan Copy Number (CN) Assays were performed according
to the manufacturer’s instructions (P/Ns 4400293 and 4400296,
Applied Biosystems, Foster City, CA). In all, the copy numbers of
23 genes of interest were measured across 23 samples, derived
from six normal tissues, 14 tumors, and two Coriell Institute for
Medical Research (Camden, NJ) gDNA controls (see Table S7 for
assay details). For each gene of interest, four replicate CT values
were obtained per sample with FAM
TM-labeled and VICH-labeled
probes, assaying the gene of interest and a control gene,
respectively. Both RNaseP and TERT were used as controls in
separate assays (P/Ns 4403328 and 4403315, Applied Biosystems).
Four dCT values were calculated by subtracting each VIC CT
from the corresponding FAM CT. A single ddCT value,
estimating the CN fold-change in a particular tumor sample,
was calculated by subtracting the median of median dCTs of the
six normal samples from the median dCT value for that particular
tumor sample. The null hypothesis that the CN fold-change is zero
was tested by a t-test in which variance was estimated by pooling
the 24 dCT values from normal samples. This hypothesis was
rejected and the CN fold-change deemed significant for p,0.05.
Genes with significant CN fold-changes in two separate assays (one
using the RNaseP locus as a control and the other using TERT)
are highlighted in Figure S7.
Copy Number Validation by Microarray (aCGH)
aCGH was performed using the Agilent Human Genome
Microarray Kit 244K (Agilent Technologies, Santa Clara, CA)
which contains ,244,000 60-mer oligonucleotide probes spanning
coding and non-coding genomic sequences with median spacing of
7.4 and 16.5 kb respectively. Arrays were analyzed using the
Genepix 4200A scanner (Axon Instruments, Union City, CA) and
the Agilent Feature Extraction software (v9.1). Copy number
segments were obtained with the Agilent CGH Analytics software
(v.3.4), using the ADM-1 algorithm and default settings [73].
Supporting Information
Figure S1 Whole transcriptome (WT) experimental protocol.
The protocol used to prepare total RNA for SOLiD sequencing is
diagrammed above. This approach achieves strand-specificity by
employing end-specific ligation of sequencing adapters to RNA,
prior to the cDNA synthesis step. The P1 sequencing adapter is an
RNA/DNA complex that contains a 6 bp 39 single-strand DNA
overhang allowing it to hybridize only to the 59 end of an RNA
fragment/molecule and, likewise, the P2 adapter will hybridize
only to the 39 end. The ligase used is engineered specifically to
prefer the types of double-stranded substrates produced by these
hybridizations, effectively making proper hybridization a prereq-
uisite for efficient ligation. So, when cDNA is sequenced off the P1
adapter we expect the read sequence to represent the underlying
RNA in the 59-.39 orientation and thus, after alignment, we can
work out the genomic strand from which the RNA originated.
Also, because RNA is fragmented prior to cDNA synthesis, the
protocol is less biased with respect to the positional origin of inserts
within transcripts.
Found at: doi:10.1371/journal.pone.0009317.s001 (0.98 MB TIF)
Figure S2 Whole transcriptome (WT) alignment strategy. WT
sequencing reads were analyzed using Applied Biosystems whole
transcriptome software tools (http://solidsoftwaretools.com/gf/
project/transcriptome/). Briefly, the reads generated from each
sample are aligned to the human genome (hg18, NCBI Build
36.1). Given the size of our 50-base reads relative to average exon
length (150 bases), we anticipated that a substantial fraction of
reads (up to one third) will cover a splice junction. Hence, these
reads will not align contiguously to the genome and standard read
mapping methods (e.g., MAQ) will fail. Making the assumption
that at least half of each read sequence originates from a
contiguous region of the genome, we circumvented this problem
by splitting each read into two 25 base non-overlapping halves and
then mapping each read split to the genome independently using
Applied Biosystems’ color mapping tool (http://solidsoftwaretools.
com/gf/project/mapreads/). During this mapping phase we
allowed up to two mismatches and removed reads that align to
more than 10 locations. The mapping of each half was extended
along the mapped genomic region using colors from the other half
until a maximal score was reached (+1 for a match and 21 for a
mismatch). In cases where the read splits aligned to the same
genomic location (i.e., cases where the read likely originated from
a segment of RNA that did not contain a splice junction), the
results from the two halves were merged. Alignment locations were
subsequently used to generate counts for annotated exons,
transcripts, and genes, as well as genomic coverage plots (WIG
files) that were displayed in the UCSC Genome Browser.
Found at: doi:10.1371/journal.pone.0009317.s002 (7.97 MB TIF)
Figure S3 RNA degradation and rRNA removal. An aliquot (1
ml; ranging from ,15–100 ng) of each of the indicated RNA
samples was processed on an Agilent Bioanalzer using a standard
RNA nano chip. A good quality RNA sample should primarily
show two distinct products representing the 18S and 28S rRNAs
and produce RIN values of ,9 using the standard bioanalyzer
conditions. While these two distinct products are visible in these
samples a large number of additional products are observed
migrating at various sizes, indicating that these samples are
compromised by degradation to varying degrees. The N8, T8 and
N33 samples showed the greatest amount of degradation (RIN
values 3.2, 4.4 and 3, respectively) while T33, N51 and T51
demonstrated less degraded RNA (RIN values 5.9, 6 and 6.1,
respectively). The degree of fragmentation has a negative impact
on the level of rRNA that can be removed from the sample using
biotinylated capture probes. Any RNA fragments that lie outside
the regions covered by the capture probes will not be effectively
removed and can be captured and sequenced. Therefore,
degraded RNA samples are expected to produce a higher number
of tags representing rRNA than high quality intact RNA samples.
Found at: doi:10.1371/journal.pone.0009317.s003 (7.99 MB TIF)
Figure S4 Validation of SOLiD whole transcriptome analysis
with other gene expression measurement platforms. (A) Compar-
ison of log2 (Tumor/Normal) values measured by the BeadArray
microarray and SOLiD sequencing platforms. Pearson correla-
tions are shown between the platforms, both within and between
patients. (B–D) For each patient, a scatterplot of log2 (Tumor/
Normal) values as measured by the BeadArray microarray and
SOLiD sequencing platforms is shown. Points are colored by
transcript abundance (blue indicating low and red indicating high
abundance; there are roughly 5000 genes in each bin), revealing
greater discordance for genes with low expression. (E–F) Eight
down-regulated and eight up-regulated genes with expression
measurements that were discordant between the SOLiD and
BeadArray platforms were chosen for validation with TaqMan
gene expression assays. Displayed are scatterplot comparisons of
log2 (Tumor/Normal) expression as measured by (E) SOLiD and
TaqMan (r=0.84), and (F) BeadArray and TaqMan (r=0.71).
Found at: doi:10.1371/journal.pone.0009317.s004 (9.79 MB TIF)
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contains histograms of allelic ratios for genomic positions in
patients 8, 33, and 51 (as labeled). For a given genomic coordinate,
the ‘‘allelic ratio’’ is the log2 of the number of reads aligned across
that position that indicate the reference nucleotide divided by the
number of reads that indicate the first non-reference nucleotide in
dbSNP. Thus we only concern ourselves here with the subset of
genomic positions for which an allele is listed in dbSNP and to
which at least 15 reads are aligned. As expected if alleles tend to be
expressed at equal levels, we see a trimodal distribution of allelic
ratios, representing the three possible genotypes: homozygous
reference, heterozygous and homozygous non-reference. Allelic
ratio distributions for normal tissue samples and tumors are shown
in red and blue, respectively. The bottom row contains histograms
of x
2 allelic imbalance P-values for genomic positions in patients 8,
33, and 51 (as labeled). The P-values indicate the extent of allelic
imbalance at a transcriptomic position and are calculated in the
following manner: First di-colors from reads aligned to that
position that represent either a reference nucleotide or a single
nucleotide substitution are tallied. Invalid di-colors, which likely
represent sequencing errors or more complex mutations, are
filtered from further analysis. The nucleotide frequencies are then
compared between samples (normal and tumor) by applying a x
2
test of independence (on a 264 contingency table). The true and
simulated x
2 allelic imbalance P-value distributions are shown in
red and blue, respectively. The true distribution is shifted to the
right relative to the simulated distribution, signifying that many
transcriptomic positions differ in nucleotide frequencies between
normal and tumor samples more than expected by sampling alone.
Found at: doi:10.1371/journal.pone.0009317.s005 (1.65 MB TIF)
Figure S6 Validation of allelic imbalance. In our first round of
validation, 27 transcriptomic positions identified by SOLiD
sequencing to have AI were selected for genotyping and validation
by allele-specific PCR (as-RT-qPCR). (A) The 27 positions and
various associated statistics are listed, one position per row. The
‘‘p-value’’ indicates the significance of relative AI between
conditions and is calculated from a x
2 test of independence on
the read counts (Methods). A ‘‘read count’’ is simply the number of
reads aligned across the transcriptomic position that indicate the
given nucleotide. Because our fragment sequence read length is
50, it is theoretically possible that reads aligned across a given
transcriptomic position could have as many as 50 ‘‘unique read
start positions’’ in the transcriptome (due to alternative splicing,
the number could actually be higher in some cases). The rows are
ordered by validation success (first 9 rows represent validated
positions and the last 18 rows represent positions that did not
validate) and a clear pattern emerges: most of our false positives,
but not our true positives, have one nucleotide in one biological
sample that is supported only by reads with the same alignment
start in the transcriptome. That particular nucleotide tends not to
be present in dbSNP and is not present according to as-qPCR of
genomic DNA. One scenario that would lead to this phenomenon
is an error introduced during reverse transcription that subse-
quently gets amplified in library preparation and later over-
sampled during sequencing. Please see the Methods section for our
refined strategy, which reduces the false positive rate retrospec-
tively from 67% to 7% on the first round validation data.
N=normal and T=tumor. (B) On a second round validation of
32 additional sites chosen prospectively with the revised strategy
the false positive rate dropped to 43%. The fraction of sites falsely
ascribed heterozygous genotypes based on RNA-Seq dropped
from 49% in the first round to 7% in the second round of
valdiation. (C) A scatter plot of relative AI values produced by
SOLiD sequencing (X-axis) and as-RT-qPCR (Y-axis). Here, we
combine all transcriptomic positions assayed in the first and
second rounds of validation that passed the revised criteria and
had genotypes that were concordant between RNA-Seq and as-
qPCR of genomic DNA (N=37).
Found at: doi:10.1371/journal.pone.0009317.s006 (3.96 MB TIF)
Figure S7 Validation of SOLiD CNV analysis with other CNV
measurement platforms and across a panel of tumor samples.
Comparison of SOLiD results to results from (A) TaqMan CNV
assays and (B) Agilent 244K CNV microarrays. (A) There is strong
concordance of copy number changes as measured by TaqMan
and SOLiD across 23 assayed genes (r=0.99). (B) Only high
confidence results from the microarray platform (colored red)
compare favorably with the SOLiD results (r=0.97). Most of the
low confidence microarray results (colored blue) are measured by a
single probe, rather than multiple probes, on the array. (C) In
addition to the tumor and matched normal samples of patient 8
(labeled ‘‘8_1’’), the 23 TaqMan CNV assays (interrogating 23
genes of interest) were applied to a panel of 13 other tumor
samples and a second section of normal/tumor tissue from patient
8 (labeled ‘‘8_2’’). Two negative control gDNAs from Coriell were
also assayed. Shaded in blue and yellow are genes with significant
copy number decreases and increases, respectively (t-test; p-
value,0.05 for two separate assays, using either the RNAseP
or TERT loci as controls). Values listed are log2 (Tumor/
Normalmedian). Matched normal tissues were only available for 5 of
the 13 tumors, thus the median of the normal samples was used as
the ‘‘normal sample’’ for each tumor/normal comparison and the
variance for each t-test was estimated from the pool of normals. In
general, the variance among normal samples is low; for patients
where matched normal tissue is available, using the median
normal rather than the true matched normal provides very similar
measurements of copy number change.
Found at: doi:10.1371/journal.pone.0009317.s007 (9.41 MB TIF)
Text S1 Coverage of annotated exons, transcripts and genes.
Found at: doi:10.1371/journal.pone.0009317.s008 (0.03 MB
DOC)
Table S1 Normalized transcript counts and differential (tumor
versus normal) transcript expression values measured by RNA-Seq.
Found at: doi:10.1371/journal.pone.0009317.s009 (7.66 MB
XLS)
Table S2 Differential (tumor versus normal) gene expression
values measured by microarray hybridization and RNA-Seq.
Found at: doi:10.1371/journal.pone.0009317.s010 (5.96 MB
XLS)
Table S3 The three hundred most up-regulated and down-
regulated genes in a comparison of tumor to normal tissue across
the three patients.
Found at: doi:10.1371/journal.pone.0009317.s011 (0.04 MB
XLS)
Table S4 Genes that are allelically imbalanced in tumor versus
normal comparisons of at least one patient.
Found at: doi:10.1371/journal.pone.0009317.s012 (0.05 MB
XLS)
Table S5 Genes that are allelically imbalanced in tumor versus
normal comparisons of at least two patients. Genomic positions
examined and other details provided.
Found at: doi:10.1371/journal.pone.0009317.s013 (0.09 MB
PDF)
Table S6 Copy number changes of genomic segments in patient
8.
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Table S7 Copy number assay details.
Found at: doi:10.1371/journal.pone.0009317.s015 (0.02 MB
XLS)
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